Influenza immunization of pregnant women in low and middle income - - PowerPoint PPT Presentation

influenza immunization of pregnant
SMART_READER_LITE
LIVE PREVIEW

Influenza immunization of pregnant women in low and middle income - - PowerPoint PPT Presentation

Influenza immunization of pregnant women in low and middle income countries: Lessons learned Alan R. Hinman, MD, MPH Technical Consultation on Maternal Influenza Immunization Evidence and Implementation March 26, 2015 Outline of


slide-1
SLIDE 1

Influenza immunization of pregnant women in low and middle income countries: Lessons learned

Alan R. Hinman, MD, MPH Technical Consultation on Maternal Influenza Immunization Evidence and Implementation March 26, 2015

slide-2
SLIDE 2

Outline of presentation

  • Partnership for Influenza Vaccine Introduction

(PIVI) – History – Countries involved

  • Pregnant women immunized 2012-2014
  • Features of PIVI
  • Lessons learned

Although PIVI is concerned with all SAGE- identified priority groups, this presentation will focus on vaccination of pregnant women

slide-3
SLIDE 3

PIVI Terms of Reference

  • Vision - Equitable access to seasonal

influenza vaccines

  • Mission - To reduce morbidity and mortality
  • f influenza in low- and middle-income

countries (LMICs) by working with a wide range of global stakeholders to foster creation of sustainable national annual influenza vaccination programs

slide-4
SLIDE 4

Development of PIVI

slide-5
SLIDE 5

Evolution of PIVI

  • 2012

– 375,000 doses of excess NH Novartis influenza vaccine from Walgreens donated to Lao PDR

  • 2013

– 100,000 doses donated SH bioCSL to Lao PDR – 35,000 doses SH to Nicaragua (through PAHO Revolving Fund) – Grant from BMGF to expand PIVI

  • 2014

– 763,000 doses donated SH bioCSL to Lao PDR – ~32,000 doses SH Green Cross to Nicaragua (through PAHO RF) – 60,000 doses donated SH Green Cross to Armenia – 123,000 doses donated SH Green Cross to Morocco

slide-6
SLIDE 6

Pregnant women vaccinated with PIVI- provided vaccine

Lao PDR Nicaragua 2012 29,213

  • 2013

14,035 27,121 2014 36,173 24,997* Total 79,421 52,118 Grand total 131,539

*Nicaragua also purchased 95,000 doses with national funds so all 128,000 pregnant women in the country could be vaccinated

slide-7
SLIDE 7

PIVI Evaluations

Partner countries required to conduct program evaluations to inform country sustainability (and global evidence base) Operational:

  • post-introduction evaluations (PIE)
  • vaccine coverage/wastage
  • effect of flu vax on other health programs
  • program costs/requirements
  • year-round vs. annual delivery

Safety:

  • adverse event monitoring (e.g. pregnancy
  • utcomes )

Health impact: -focus in 2013-14 on effect of vaccine on infant outcomes (e.g. birth weight, prematurity)

  • modeled impact and cost-effectiveness
slide-8
SLIDE 8

Evaluations of vaccine effect on birth outcomes - 2014

  • Conducted in Laos and Nicaragua
  • Pilot of data collection and feasibility in 2013
  • Enrollment in 2014

– Spring-summer vaccination – Follow-up completed by Q1 2015

  • Laos

– Sites: 3 hospitals (Vientiane [2], Luangprabang) – Enrolled women – 5,000

  • Nicaragua

– Sites: 2 hospitals (Managua) – Enrolled women – 4,000

  • Expected results – Q3 2015
slide-9
SLIDE 9

Planned evaluations - 2015

  • PIE – Morocco, Armenia, (Cote d’Ivoire)
  • Feasibility and impact of year-round vs annual

vaccination – Laos, (Kenya)

  • Cost, cost-effectiveness – Laos, Morocco, (Kenya)
  • AEFI – (Cote d’Ivoire)
  • Vaccine effectiveness to prevent respiratory

disease in infants (Laos – 2016)

  • Modelled impact of vaccination – Laos, (Kenya)
slide-10
SLIDE 10

Progress towards sustainability

  • Laos

– 2014 – program costs borne by MoH – 2015 – MoH to support program and may purchase 25K doses of vaccine

  • Nicaragua

– 2014 – 33K doses provided by PIVI; 95K doses purchased by MoH to ensure vaccine accessibility to all pregnant women in country

  • Armenia

– Following 2014-5 PIVI donation, have increased flu vaccine purchase for 2015-6

  • Morocco

– PIVI donation in 2014 to be followed by increased MoH purchase in 2015

  • (Kenya)

– PIVI to support 2-3 year phased introduction, followed by MoH support of program (pending MoH decision)

slide-11
SLIDE 11

Features of PIVI - 1

  • Large public-private partnership including:

– Ministries of Health in partner countries – The Task Force for Global Health – Centers for Disease Control and Prevention – Non-governmental organizations – The Bill & Melinda Gates Foundation – Vaccine manufacturers – Vaccine distributors – Other stakeholders, eg.,

  • WHO HQ and Regional Offices
  • WHO Country Offices
slide-12
SLIDE 12

Features of PIVI - 2

  • Focus on building capacity in low and low-

middle income countries to introduce and implement influenza immunization through – Technical assistance – Training – Provision of vaccines/supplies

  • Aim to foster sustainable influenza

immunization programs

  • Country partners selected based on

readiness and interest

slide-13
SLIDE 13

Features of PIVI - 3

  • An implementation project rather than a

research project

  • Evaluations designed to identify factors

facilitating/impeding influenza vaccine implementation

  • To date has relied on donations of funds or

vaccines, which have come late in the season

  • Currently exploring purchase options
slide-14
SLIDE 14

Implementation lessons learned - 1

  • Close collaboration between EPI and ANC

programs is essential – This is not always the case at the outset – ANC staff may not be adept/practiced at immunizing pregnant women – Mere proximity of services may not be adequate

  • One-stop shopping enhances

participation – Avoids two waits for service – With effort and good will, collaboration can be achieved

slide-15
SLIDE 15

Implementation lessons learned - 2

  • In both Lao PDR and Nicaragua, EPI staff

supplemented MCH staff as major providers

  • f immunization in ANC clinics as well as

“campaigns”

  • Combination of maternal immunization with
  • ther MCH activities (e.g., vitamin A

distribution, deworming, tetanus toxoid was effective)

slide-16
SLIDE 16

Implementation lessons learned - 3

  • Step-wise addition of sites and complexity of

data gathered was effective in increasing the complexity of studies—layering new information in successive years

  • Country MCH and EPI staff are interested in

year-round maternal influenza immunization activities

slide-17
SLIDE 17

Implementation lessons learned - 4

  • Obtaining vaccine commitments in advance
  • f the season rather than relying on later

donations will enable more effective planning and implementation of maternal influenza immunization activities

  • Purchasing vaccine at a discount will

promote a more sustainable program

slide-18
SLIDE 18

Implementation lessons learned - 5

  • Single dose pre-filled syringes (PFS) are

preferred by staff for non-campaign approaches for convenience and to prevent wastage – However, PFS markedly increase storage/cold chain capacity requirements

slide-19
SLIDE 19

Health lessons learned

  • In Lao PDR and Nicaragua, pregnant women

were very accepting of influenza vaccination

  • Preliminary indications are that there may be

more hesitancy in pregnant women in Armenia and Morocco

  • No serious AEFIs were encountered
  • Minor AEFIs were as expected
  • Impact on outcome of pregnancy being

analyzed – Preliminary indications suggest no increased risk to fetus/newborn

slide-20
SLIDE 20

Conclusions

  • To date, more than 130,000 pregnant women

have received influenza vaccine through PIVI – In total, >1.4 million persons have received influenza vaccine through PIVI

  • PIVI has shown it is feasible to introduce

influenza immunization of pregnant women in developing countries

  • Important lessons have been learned about

introduction of influenza vaccine in developing countries